Once-Daily Tiotropium Respimat Add-on to Inhaled Corticosteroids Over 1 Year Improves Lung Function in Adolescent Patients With Moderate Symptomatic Asthma, Independent of Patients Baseline Characteristics

CHEST Journal ◽  
2015 ◽  
Vol 148 (4) ◽  
pp. 720A
Author(s):  
Mark Vandewalker ◽  
Thomas Harper ◽  
Petra Moroni-Zentgraf ◽  
Michael Engel ◽  
Reinhold Luehmann ◽  
...  
Keyword(s):  
Lung Function ◽  
Inhaled Corticosteroids ◽  
Once Daily ◽  
Adolescent Patients ◽  
Symptomatic Asthma ◽  
Baseline Characteristics

Once-Daily Tiotropium Respimat Added-On to Inhaled Corticosteroids in a 1-Year Study in Adolescent Patients With Symptomatic Asthma Is Efficacious and Well Tolerated

CHEST Journal ◽  
2014 ◽  
Vol 146 (4) ◽  
pp. 699A
Author(s):  
Jonathan Bernstein ◽  
Attilio Boner ◽  
Eckard Hamelmann ◽  
Mandy Avis ◽  
John Downie ◽  
...  
Keyword(s):  
Inhaled Corticosteroids ◽  
Once Daily ◽  
Adolescent Patients ◽  
Symptomatic Asthma

Efficacy and Safety of Once-daily Tiotropium Respimat®Add-on Therapy over 1 Year in Adolescent Patients with Moderate Symptomatic Asthma

PEDIATRICS ◽  
2016 ◽  
Vol 137 (Supplement 3) ◽  
pp. 203A-203A
Author(s):  
Lyndon Mansfield ◽  
Petra Moroni-Zentgraf ◽  
Michael Engel ◽  
Mandy Avis ◽  
Reinhold Lühmann ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Once Daily ◽  
Adolescent Patients ◽  
Symptomatic Asthma

scholarly journals Tiotropium Respimat® add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics

2019 ◽  
Vol 158 ◽  
pp. 97-109 ◽  
Author(s):  
Thomas B. Casale ◽  
René Aalbers ◽  
Eugene R. Bleecker ◽  
Eli O. Meltzer ◽  
Liliana Zaremba-Pechmann ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Inhaled Corticosteroids ◽  
Symptomatic Asthma ◽  
Baseline Characteristics

scholarly journals Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Claus F. Vogelmeier ◽  
Paul W. Jones ◽  
Edward M. Kerwin ◽  
Isabelle H. Boucot ◽  
François Maltais ◽  
...  
Keyword(s):  
Lung Function ◽  
Rescue Medication ◽  
Inhaled Corticosteroids ◽  
Full Range ◽  
Medication Use ◽  
Airflow Limitation ◽  
Chronic Obstructive ◽  
Double Blind ◽  
Once Daily ◽  
Post Hoc

Abstract Background In patients with chronic obstructive pulmonary disease (COPD), the relationship between short-term bronchodilator reversibility and longer-term response to bronchodilators is unclear. Here, we investigated whether the efficacy of long-acting bronchodilators is associated with reversibility of airflow limitation in patients with COPD with a low exacerbation risk not receiving inhaled corticosteroids. Methods The double-blind, double-dummy EMAX trial randomised patients to umeclidinium/vilanterol 62.5/25 µg once daily, umeclidinium 62.5 µg once daily, or salmeterol 50 µg twice daily. Bronchodilator reversibility to salbutamol was measured once at screening and defined as an increase in forced expiratory volume in 1 s (FEV1) of ≥ 12% and ≥ 200 mL 10−30 min post salbutamol. Post hoc, fractional polynomial (FP) modelling was conducted using the degree of reversibility (mL) at screening as a continuous variable to investigate its relationship to mean change from baseline in trough FEV1 and self-administered computerised-Transition Dyspnoea Index (SAC-TDI) at Week 24, Evaluating Respiratory Symptoms-COPD (E-RS) at Weeks 21–24, and rescue medication use (puffs/day) over Weeks 1–24. Analyses were conducted across the full range of reversibility (−850–896 mL); however, results are presented for the range −100–400 mL because there were few participants with values outside this range. Results The mean (standard deviation) reversibility was 130 mL (156) and the median was 113 mL; 625/2425 (26%) patients were reversible. There was a trend towards greater improvements in trough FEV1, SAC-TDI, E-RS and rescue medication use with umeclidinium/vilanterol with higher reversibility. Improvements in trough FEV1 and reductions in rescue medication use were greater with umeclidinium/vilanterol compared with either monotherapy across the range of reversibility. Greater improvements in SAC-TDI and E-RS total scores were observed with umeclidinium/vilanterol versus monotherapy in the middle of the reversibility range. Conclusions FP analyses suggest that patients with higher levels of reversibility have greater improvements in lung function and symptoms in response to bronchodilators. Improvements in lung function and rescue medication use were greater with umeclidinium/vilanterol versus monotherapy across the full range of reversibility, suggesting that the dual bronchodilator umeclidinium/vilanterol may be an appropriate treatment for patients with symptomatic COPD, regardless of their level of reversibility.

Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: lung function and safety

Pneumologie ◽  
2014 ◽  
Vol 68 (S 01) ◽  
Author(s):  
O Schmidt ◽  
HAM Kerstjens ◽  
E Bleecker ◽  
E Meltzer ◽  
T Casale ◽  
...  
Keyword(s):  
Lung Function ◽  
Inhaled Corticosteroids ◽  
Symptomatic Asthma

Once-Daily Tiotropium Respimat Add-On to Medium-Dose ICS Is an Efficacious 24-Hour Bronchodilator in Adolescent Patients With Symptomatic Asthma

CHEST Journal ◽  
2014 ◽  
Vol 146 (4) ◽  
pp. 698A ◽  
Author(s):  
Christian Vogelberg ◽  
Michael Engel ◽  
Petra Moroni-Zentgraf ◽  
Migle Leonaviciute-Klimantaviciene ◽  
Ralf Sigmund ◽  
...  
Keyword(s):  
Once Daily ◽  
Adolescent Patients ◽  
Symptomatic Asthma ◽  
Medium Dose
Sign in / Sign up

Export Citation Format

Share Document